Venture Life Group (VLG) H1 2025 earnings summary

Executive summary

• Revenue from continuing operations grew 43.1% to £15.4m, with 12.5% organic/proforma growth, driven by strategic marketing, Health & Her acquisition, and a shift to a brand-focused, higher-margin platform.

• Divestment of CDMO and non-core assets completed for €62m–€65m, transforming the business and generating significant cash reserves.

• Integration of Health & Her and new board appointments, including digital and technology leadership, support innovation and digital transformation.

• Share buyback program authorized for up to 12.8m shares, reflecting confidence in undervalued shares.

• The business is now a brand-focused, higher-margin platform with a clear M&A strategy and substantial cash resources.

Financial highlights

• Group revenue rose 43.1% to £15.4m, with 12.5% organic/proforma growth.

• Gross profit increased 49.9% to £6.6m; gross margin improved to 43.1% (up from 41.2%).

• Adjusted EBITDA up 32.6% to £1.8m; margin declined to 11.6% (2024: 12.6%) due to higher marketing spend.

• Free cash flow before exceptionals stable at £2.2m; reported free cash flow down to £1.5m due to exceptional costs.

• Net cash position of £34.1m at end of September 2025, with all debt repaid and access to £50m in credit facilities.

Outlook and guidance

• Expectation of stronger H2 performance due to seasonality and international order patterns.

• Targeting gross margins above 50% and annualized EBITDA margins over 25% within three years.

• Continued investment in marketing, innovation, and digital transformation to drive organic growth and margin improvement.

• M&A remains a key focus, with significant firepower for acquisitions in complementary categories.

• Board confident in meeting management expectations for the 17-month period ending 31 May 2026.